A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05895552 |
|
Recruitment Status :
Recruiting
First Posted : June 8, 2023
Last Update Posted : February 2, 2024
|
Sponsor:
Reata, a wholly owned subsidiary of Biogen
Information provided by (Responsible Party):
Biogen ( Reata, a wholly owned subsidiary of Biogen )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and PK of RTA 901 in qualified subjects with DPNP. Each study part will be randomized into 3 treatment arms; 2 different doses of RTA 901 and a Placebo. The doses of RTA 901 in Part 2 will be selected based on the Exposure-Response (E-R) analyses of data from Part 1. A total of 384 subjects will be randomized in this study. Each part will have 192 subjects, with 64 subjects randomized 1:1:1 to each treatment arm.
The duration of each part of the study will be approximately 20 weeks, including a Screening Period of up to 2 weeks, a Run-in Period of 2 weeks, a Treatment Period of 12 weeks, and a Follow-up Period of 4 weeks. All subjects in Part 1 and Part 2 of the study will follow the same visit and assessment schedule. Eligibility will be assessed during the Screening and Run-in Periods.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Diabetic Peripheral Neuropathic Pain | Drug: RTA 901 Drug: Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 384 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2 Study to Evaluate the Safety and Efficacy of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) |
| Actual Study Start Date : | August 21, 2023 |
| Estimated Primary Completion Date : | August 1, 2026 |
| Estimated Study Completion Date : | August 1, 2026 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Part 1 RTA 901 Dose 1
Subjects will receive study drug once daily during the 2-week Run-in Period. Following randomization, the subjects will receive a dose of RTA 901 once daily for a 12-week treatment duration.
|
Drug: RTA 901
RTA 901 capsules will be administered once daily during a fasted state in either Dose 1 or Dose 2.
Other Name: cemdomespib |
|
Experimental: Part 1 RTA 901 Dose 2
Subjects will receive study drug once daily during the 2-week Run-in Period. Following randomization, the subjects will receive a dose of RTA 901 once daily for a 12-week treatment duration.
|
Drug: RTA 901
RTA 901 capsules will be administered once daily during a fasted state in either Dose 1 or Dose 2.
Other Name: cemdomespib |
|
Placebo Comparator: Part 1 Placebo
Subjects will receive study drug once daily during the 2-week Run-in Period. Following randomization, the subjects will receive a dose of Placebo once daily for a 12-week treatment duration.
|
Drug: Placebo
Matching placebo capsules will be administered once daily during a fasted state. |
|
Experimental: Part 2 RTA 901 Dose 1
Subjects will receive study drug once daily during the 2-week Run-in Period. Following randomization, the subjects will receive a dose of RTA 901 once daily for a 12-week treatment duration.
|
Drug: RTA 901
RTA 901 capsules will be administered once daily during a fasted state in either Dose 1 or Dose 2.
Other Name: cemdomespib |
|
Experimental: Part 2 RTA 901 Dose 2
Subjects will receive study drug once daily during the 2-week Run-in Period. Following randomization, the subjects will receive a dose of RTA 901 once daily for a 12-week treatment duration.
|
Drug: RTA 901
RTA 901 capsules will be administered once daily during a fasted state in either Dose 1 or Dose 2.
Other Name: cemdomespib |
|
Placebo Comparator: Part 2 Placebo
Subjects will receive study drug once daily during the 2-week Run-in Period. Following randomization, the subjects will receive a dose of Placebo once daily for a 12-week treatment duration.
|
Drug: Placebo
Matching placebo capsules will be administered once daily during a fasted state. |
Primary Outcome Measures :
- Measure the change from baseline in average pain intensity as assessed by the Numeric Pain Rating Scale (NPRS) [ Time Frame: 12 weeks ]The efficacy of RTA 901 will be assessed using the NPRS for patients receiving active drug compared to patients receiving placebo. The NPRS is an 11-point numeric scale, which ranges from '0' representing 'no pain' to '10' representing the 'worst pain imaginable'. Lower scores indicate less pain.
- Count of reported adverse events [ Time Frame: 20 weeks ]Safety and tolerability will be assessed by counting adverse events, as defined by the Medical Dictionary for Regulatory Activities (MedDRA) during the study duration.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adult male and female subjects ≥ 18 years of age upon study consent;
- Diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) at least 1 year prior to Screening;
- Clinical diagnosis of Diabetic Peripheral Neuropathic Pain (DPNP) defined as symptomatic distal symmetric polyneuropathy (secondary to diabetes) in the lower extremities, which may include symptoms of pain that is burning, lancinating, tingling, or shooting (electric shock-like);
- Currently taking only 1 allowed prescribed standard-of-care pain medication for managing DPNP at a stable dose (not exceeding the maximum dose in the prescribing information) for approximately 4 weeks prior to Screening;
- NPRS pain intensity score ≥ 4 on an 11-point scale at Screening.
Exclusion Criteria:
- Has neuropathy from a cause other than type 1 diabetes mellitus or type 2 diabetes mellitus;
- Has a condition other than DPNP that could confound the assessment of pain (eg, fibromyalgia or regional pain caused by lumbar or cervical compression);
- Diabetic foot ulceration or infection within 90 days prior to Screening;
- Has had more than 1 episode of ketoacidosis or hyperosmolar state requiring hospitalization within 90 days prior to Screening;
- Has had more than 3 episodes of hypoglycemia requiring medical assistance within 90 days prior to Screening;
- Serum aminotransferase (alanine aminotransferase or aspartate aminotransferase) levels > 1.5× the upper limit of normal (ULN);
- History of malignancy within 3 years prior to Screening, except for non-melanoma skin tumor, cervical carcinomas in situ, or successfully treated malignancies in remission;
- Unwilling to practice methods of birth control during Screening, while taking study drug, and for at least 30 days after the last dose of study drug is ingested;
- Women who are pregnant or breastfeeding;
- Use of the prohibited medications, devices, or procedures.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05895552
Contacts
| Contact: US Biogen Clinical Trial Center | 866-633-4636 | clinicaltrials@biogen.com | |
| Contact: Global Biogen Clinical Trial Center | clinicaltrials@biogen.com |
Locations
Show 36 study locations
Sponsors and Collaborators
Reata, a wholly owned subsidiary of Biogen
| Responsible Party: | Reata, a wholly owned subsidiary of Biogen |
| ClinicalTrials.gov Identifier: | NCT05895552 |
| Other Study ID Numbers: |
901-C-2102 |
| First Posted: | June 8, 2023 Key Record Dates |
| Last Update Posted: | February 2, 2024 |
| Last Verified: | February 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/ |
| URL: | https://vivli.org/ |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Biogen ( Reata, a wholly owned subsidiary of Biogen ):
|
RTA 901 Diabetic Peripheral Neuropathic Pain DPNP |
Additional relevant MeSH terms:
|
Neuralgia Diabetic Neuropathies Peripheral Nervous System Diseases Neuromuscular Diseases Nervous System Diseases |
Pain Neurologic Manifestations Diabetes Complications Diabetes Mellitus Endocrine System Diseases |